Proteomic identification of protease cleavage sites: Cell-biological and biomedical applications

Expert Review of Proteomics

Volumn 10, Issue 5, 2013, Pages 421-433

  Shahinian, Hasmik ^a   Tholen, Stefan ^b   Schilling, Oliver ^b  

^a UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

caspases; cathepsins; degradomics; granzymes; limited proteolysis; matrix metalloproteinases; peptidomics; pharmacological protease inhibition; protease specificity

Indexed keywords

ASPARTIC ACID; CATHEPSIN; GRANZYME; MATRIX METALLOPROTEINASE; PROTEINASE;

CYTOLOGY; PEPTIDOMICS; PROTEIN DEGRADATION; PROTEIN PROCESSING; PROTEOMICS; REVIEW;

ANIMALS; APOPTOSIS; CASPASES; CATHEPSINS; DIPEPTIDYL-PEPTIDASES AND TRIPEPTIDYL-PEPTIDASES; GRANZYMES; HUMANS; MATRIX METALLOPROTEINASES; MITOCHONDRIAL PROTEINS; PEPTIDE HYDROLASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOLYSIS; PROTEOMICS; SUBSTRATE SPECIFICITY; TIOPRONIN;

EID: 84886026003     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.2013.841547     Document Type: Review

References (132)

1. McQuibban GA, Gong JH, Tam EM, McCulloch CA, Clark-Lewis I, Overall CM. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 289(5482), 1202-1206 (2000).
2. Broxmeyer HE, Hoggatt J, O'Leary HA et al. Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis. Nat. Med. 18(12), 1786-1796 (2012).
3. Scheller J, Chalaris A, Garbers C, Rose-John S. ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol. 32(8), 380-387 (2011).
4. Quesada V, Ordóñez GR, Sánchez LM, Puente XS, López-Ot?́n C. The Degradome database: mammalian proteases and diseases of proteolysis. Nucleic Acids Res. 37(Database issue), D239-D243 (2009).
5. Kappelhoff R, Overall C. The CLIP-CHIP oligonucleotide microarray: dedicated array for analysis of all protease, nonproteolytic homolog, and inhibitor gene transcripts in human and mouse. Curr. Protoc. Protein Sci. Chapter 21, Unit 21.19 (2007).
6. Overall CM, Tam EM, Kappelhoff R et al. Protease degradomics: mass spectrometry discovery of protease substrates and the CLIP-CHIP, a dedicated DNA microarray of all human proteases and inhibitors. Biol. Chem. 385(6), 493-504 (2004).
7. Murphy G. Tissue inhibitors of metalloproteinases. Genome. Biol. 12(11), 233 (2011).
8. Turk V, Bode W. The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett. 285(2), 213-219 (1991).
9. Silverman GA, Whisstock JC, Bottomley SP et al. Serpins flex their muscle: I. Putting the clamps on proteolysis in diverse biological systems. J. Biol. Chem. 285(32), 24299-24305 (2010).
10. Roberts RM, Mathialagan N, Duffy JY, Smith GW. Regulation and regulatory role of proteinase inhibitors. Crit. Rev. Eukaryot. Gene Expr. 5(3-4),385-436 (1995).
11. Overall CM, Blobel CP. In search of partners: linking extracellular proteases to substrates. Nat. Rev. Mol. Cell. Biol. 8(3), 245-257 (2007).
12. De Clercq E. The design of drugs for HIV and HCV. Nat. Rev. Drug Discov. 6(12), 1001-1018 (2007).
13. Petrera A, Amstutz B, Gioia M et al. Functional characterization of the Mycobacterium tuberculosis zinc metallopeptidase Zmp1 and identification of potential substrates. Biol. Chem. 393(7), 631-640 (2012).
14. Bowyer PW, Simon GM, Cravatt BF, Bogyo M. Global profiling of proteolysis during rupture of Plasmodium falciparum from the host erythrocyte. Mol. Cell. Proteomics 10(5), M110.001636 (2011).
15. Rosenthal PJ. Falcipains and other cysteine proteases of malaria parasites. Adv. Exp. Med. Biol. 712), 30-48 (2011).
16. Perzborn E, Roehrig S, Straub A, Kubitza D, Misselwitz F. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat. Rev. Drug Discov. 10(1), 61-75 (2011).
17. Jensen C, Herold P, Brunner HR. Aliskiren: the first renin inhibitor for clinical treatment. Nat. Rev. Drug Discov. 7(5), 399-410 (2008).
18. Zaman MA, Oparil S, Calhoun DA. Drugs targeting the renin-angiotensin- aldosterone system. Nat. Rev. Drug Discov. 1(8), 621-636 (2002).
19. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat. Rev. Endocrinol. 5(5), 262-269 (2009).
20. Kwong AD, Kauffman RS, Hurter P, Mueller P. Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat. Biotechnol. 29(11), 993-1003 (2011).
21. Boonen S, Rosenberg E, Claessens F, Vanderschueren D, Papapoulos S. Inhibition of cathepsin K for treatment of osteoporosis. Curr. Osteoporos. Rep. 10(1), 73-79 (2012).
22. Williams SCP. Potential first-in-class osteoporosis drug speeds through trials. Nat. Med. 18(8), 1158-1158 (2012).
23. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5(5), 417-421 (2004).
24. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295(5564), 2387-2392 (2002).
25. Turk B. Targeting proteases: successes, failures and future prospects. Nat. Rev. Drug Discov. 5(9), 785 (2006).
26. López-Ot?́n C, Overall CM. Protease degradomics: a new challenge for proteomics. Nat. Rev. Mol. Cell Biol. 3(7), 509-519 (2002).
27. Schechter I, Berger A. On the active site of proteases. 3. Mapping the active site of papain; specific peptide inhibitors of papain. Biochem. Biophys. Res. Commun. 32(5), 898-902 (1968).
28. Olsen JV, Ong S-E, Mann M. Trypsin cleaves exclusively C-terminal to arginine and lysine residues. Mol. Cell Proteomics 3(6), 608-614 (2004).
29. Gál P, Barna L, Kocsis A, Závodszky P. Serine proteases of the classical and lectin pathways: similarities and differences. Immunobiology 212(4-5), 267-277 (2007).
30. Turk BE, Huang LL, Piro ET, Cantley LC. Determination of protease cleavage site motifs using mixture-based oriented peptide libraries. Nat. Biotechnol. 19(7), 661-667 (2001).
31. Schilling O, Overall CM. Proteome-derived, database-searchable peptide libraries for identifying protease cleavage sites. Nat. Biotechnol. 26(6), 685-694 (2008).
32. Impens F, Colaert N, Helsens K et al. A quantitative proteomics design for systematic identification of protease cleavage events. Mol. Cell Proteomics 9(10), 2327-2333 (2010).
33. Caescu CI, Jeschke GR, Turk BE. Active-site determinants of substrate recognition by the metalloproteinases TACE and ADAM10. Biochem. J. 424(1), 79-88 (2009).
34. Biniossek ML, Nägler DK, Becker-Pauly C, Schilling O. Proteomic identification of protease cleavage sites characterizes prime and non-prime specificity of cysteine cathepsins B, L, and S. J. Proteome Res. 10(12), 5363-5373 (2011).
35. Boyd SE, Pike RN, Rudy GB, Whisstock JC, Garcia de la Banda M. PoPS: a computational tool for modeling and predicting protease specificity. J. Bioinform. Comput. Biol. 3(3), 551-585 (2005).
36. Barkan DT, Hostetter DR, Mahrus S et al. Prediction of protease substrates using sequence and structure features. Bioinformatics 26(14), 1714-1722 (2010).
37. Lohmüller T, Wenzler D, Hagemann S et al. Toward computer-based cleavage site prediction of cysteine endopeptidases. Biol. Chem. 384(6), 899-909 (2003).
38. Schilling O, Huesgen PF, Barré O, Auf dem Keller U, Overall CM. Characterization of the prime and non-prime active site specificities of proteases by proteome-derived peptide libraries and tandem mass spectrometry. Nat. Protoc. 6(1), 111-120 (2011).
39. Becker-Pauly C, Barré O, Schilling O et al. Proteomic analyses reveal an acidic prime side specificity for the astacin metalloprotease family reflected by physiological substrates. Mol. Cell. Proteomics. 10(9), M111.009233 (2011).
40. Tholen S, Biniossek ML, Gansz M et al. Deletion of cysteine cathepsins B or L yields differential impacts on murine skin proteome and degradome. Mol. Cell. Proteomics 12(3), 611-625 (2013).
41. Tholen S, Biniossek ML, Geßler A-L et al. Contribution of cathepsin L to secretome composition and cleavage pattern of mouse embryonic fibroblasts. Biol. Chem. 392(11), 961-971 (2011).
42. Auf dem Keller U, Schilling O. Proteomic techniques and activity-based probes for the system-wide study of proteolysis. Biochimie 92(11), 1705-1714 (2010).
43. Schilling O, Overall CM. Proteomic discovery of protease substrates. Curr. Opin. Chem. Biol. 11(1), 36-45 (2007).
44. Perera NC, Schilling O, Kittel H, Back W, Kremmer E, Jenne DE. NSP4, an elastase-related protease in human neutrophils with arginine specificity. Proc. Natl Acad. Sci. USA 109(16), 6229-6234 (2012).
45. Paes Leme AF, Escalente T, Pereira JG et al. High resolution analysis of snake venom metalloproteinase (SVMP) peptide bond cleavage specificity using proteome based peptide libraries and mass spectrometry. J. Proteomics 74(4), 401-410 (2011).
46. Schilling O, dem Keller UA, Overall CM. Factor Xa subsite mapping by proteome-derived peptide libraries improved using WebPICS, a resource for proteomic identification of cleavage sites. Biol. Chem. 392(11), 1031-1037 (2011).
47. Tanco S, Lorenzo J, Garcia-Pardo J et al. Proteome-derived peptide libraries to study the substrate specificity profiles of carboxypeptidases. Mol. Cell. Proteomics. 12(8), 2096-2110 (2013).
48. Jakoby T, van den Berg BH, Tholey A. Quantitative protease cleavage site profiling using tandem-mass-tag labeling and LC-MALDI-TOF/TOF MS/MS analysis. J. Proteome. Res. 11(3), 1812-1820 (2012).
49. O'Donoghue AJ, Eroy-Reveles AA, Knudsen GM et al. Global identification of peptidase specificity by multiplex substrate profiling. Nat. Methods 9(11), 1095-1100 (2012).
50. Puente XS, Sánchez LM, Overall CM, López-Ot?́n C. Human and mouse proteases: a comparative genomic approach. Nat. Rev. Genet. 4(7), 544-558 (2003).
51. Tanco S, Zhang X, Morano C, Avilés FX, Lorenzo J, Fricker LD. Characterization of the substrate specificity of human carboxypeptidase A4 and implications for a role in extracellular peptide processing. J. Biol. Chem. 285(24), 18385-18396 (2010).
52. Sukuru SCK, Nigsch F, Quancard J et al. A lead discovery strategy driven by a comprehensive analysis of proteases in the peptide substrate space. Protein Sci. 19(11), 2096-2109 (2010).
53. Huesgen PF, Overall CM. N-and C-terminal degradomics: new approaches to reveal biological roles for plant proteases from substrate identification. Physiol. Plant 145(1), 5-17 (2012).
54. Klingler D, Hardt M. Profiling protease activities by dynamic proteomics workflows. Proteomics 12(4-5), 587-596 (2012).
55. van den Berg BHJ , Tholey A. Mass spectrometry-based proteomics strategies for protease cleavage site identification. Proteomics 12(4-5), 516-529 (2012).
56. Diamond SL. Methods for mapping protease specificity. Curr. Opin. Chem. Biol. 11(1), 46-51 (2007).
57. Hwang IK, Park SM, Kim SY, Lee ST. A proteomic approach to identify substrates of matrix metalloproteinase-14 in human plasma. Biochim. Biophys. Acta. 1702(1), 79-87 (2004).
58. Lee AY, Park BC, Jang M et al. Identification of caspase-3 degradome by two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionizationtime of flight analysis. Proteomics 4(11), 3429-3436 (2004).
59. Bredemeyer AJ, Lewis RM, Malone JP et al. A proteomic approach for the discovery of protease substrates. Proc. Natl Acad. Sci. USA 101(32), 11785-11790 (2004).
60. Thiede B, Treumann A, Kretschmer A, Söhlke J, Rudel T. Shotgun proteome analysis of protein cleavage in apoptotic cells. Proteomics 5(8), 2123-2130 (2005).
61. Dix MM, Simon GM, Cravatt BF. Global mapping of the topography and magnitude of proteolytic events in apoptosis. Cell 134(4), 679-691 (2008).
62. Hemming ML, Elias JE, Gygi SP, Selkoe DJ. Identification of beta-secretase (BACE1) substrates using quantitative proteomics. PLoS One 4(12), e8477 (2009).
63. Hemming ML, Elias JE, Gygi SP, Selkoe DJ. Proteomic profiling of gamma-secretase substrates and mapping of substrate requirements. PLoS Biol. 6(10), e257 (2008).
64. Stoehr G, Schaab C, Graumann J, Mann M. A SILAC-based approach identifies substrates of caspase-dependent cleavage upon TRAIL-induced apoptosis. Mol. Cell. Proteomics 12(5), 1436-1450 (2013).
65. Timmer JC, Enoksson M, Wildfang E et al. Profiling constitutive proteolytic events in vivo. Biochem. J. 407(1), 41-48 (2007).
66. Xu G, Shin SBY, Jaffrey SR. Global profiling of protease cleavage sites by chemoselective labeling of protein N-termini. Proc. Natl Acad. Sci. USA 106(46), 19310-19315 (2009).
67. Mahrus S, Trinidad JC, Barkan DT, Sali A, Burlingame AL, Wells JA. Global sequencing of proteolytic cleavage sites in apoptosis by specific labeling of protein N termini. Cell 134(5), 866-876 (2008).
68. Xu G, Shin SBY, Jaffrey SR. Chemoenzymatic labeling of protein C-termini for positive selection of C-terminal peptides. ACS Chem. Biol. 6(10), 1015-1020. (2011).
69. Van Damme P, Martens L, Van Damme J et al. Caspase-specific and nonspecific in vivo protein processing during Fas-induced apoptosis. Nat. Methods 2(10), 771-777 (2005).
70. Gevaert K, Goethals M, Martens L et al. Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat. Biotechnol. 21(5), 566-569 (2003).
71. Mommen GP, Van De Waterbeemd B, Meiring HD, Kersten G, Heck AJ, De Jong AP. Unbiased selective isolation of protein N-terminal peptides from complex proteome samples using phospho tagging (PTAG) and TiO2-based depletion. Mol. Cell. Proteomics 11(9), 832-842 (2012).
72. Kleifeld O, Doucet A, Auf dem Keller U et al. Isotopic labeling of terminal amines in complex samples identifies protein N-termini and protease cleavage products. Nat. Biotechnol. 28(3), 281-288 (2010).
73. Auf dem Keller U, Prudova A, Eckhard U, Fingleton B, Overall CM. Systems-level analysis of proteolytic events in increased vascular permeability and complement activation in skin inflammation. Sci. Signal. 6(258), rs2 (2013).
74. Van Damme P, Lasa M, Polevoda B et al. N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB. Proc. Natl Acad. Sci. USA 109(31), 12449-12454 (2012).
75. Van Damme P, Staes A, Bronsoms S et al. Complementary positional proteomics for screening substrates of endo-and exoproteases. Nat. Methods 7(7), 512-515 (2010).
76. Schilling O, Barré O, Huesgen PF, Overall CM. Proteome-wide analysis of protein carboxy termini: C terminomics. Nat. Methods 7(7), 508-511 (2010).
77. Akiyama TH, Sasagawa T, Suzuki M, Titani K. A method for selective isolation of the amino-terminal peptide from alpha-amino-blocked proteins. Anal. Biochem. 222(1), 210-216 (1994).
78. Coussot G, Hawke DH, Mularz A, Koomen JM, Kobayashi R. A method for the isolation of blocked N-terminal peptides. Anal. Biochem. 361(2), 302-304 (2007).
79. Kaplan H, Oda G. Selective isolation of free and blocked amino-terminal peptides from enzymatic digestion of proteins. Anal. Biochem. 132(2), 384-388 (1983).
80. Kuhn K, Thompson A, Prinz T et al. Isolation of N-terminal protein sequence tags from cyanogen bromide cleaved proteins as a novel approach to investigate hydrophobic proteins. J. Proteome. Res. 2(6), 598-609 (2003).
81. McDonald L, Robertson DHL, Hurst JL, Beynon RJ. Positional proteomics: selective recovery and analysis of N-terminal proteolytic peptides. Nat. Methods. 2(12), 955-957 (2005).
82. Mikami T, Takao T. Selective isolation of N-blocked peptides by isocyanate-coupled resin. Anal. Chem. 79(20), 7910-7915 (2007).
83. Simons BL, Wang G, Shen R-F, Knepper MA. In vacuo isotope coded alkylation technique (IVICAT); an N-terminal stable isotopic label for quantitative liquid chromatography/mass spectrometry proteomics. Rapid Commun. Mass Spectrom. 20(16), 2463-2477 (2006).
84. Agard NJ, Mahrus S, Trinidad JC, Lynn A, Burlingame AL, Wells JA. Global kinetic analysis of proteolysis via quantitative targeted proteomics. Proc. Natl Acad. Sci USA 109(6), 1913-1918 (2012).
85. Simon GM, Dix MM, Cravatt BF. Comparative assessment of large-scale proteomic studies of apoptotic proteolysis. ACS Chem. Biol. 4(6), 401-408 (2009).
86. Impens F, Van Damme P, Demol H, Van Damme J. Vandekerckhove, Gevaert. Mechanistic insight into taxol-induced cell death. Oncogene 27(33), 4580-4591 (2008).
87. Demon D, Van Damme P, Vanden Berghe T et al. Proteome-wide substrate analysis indicates substrate exclusion as a mechanism to generate caspase-7 versus caspase-3 specificity. Mol. Cell. Proteomics. 8(12), 2700-2714 (2009).
88. Vande Walle L, Van Damme P, Lamkanfi M et al. Proteome-wide Identification of HtrA2/Omi Substrates. J. Proteome Res. 6(3), 1006-1015 (2007).
89. Agard NJ, Maltby D, Wells JA. Inflammatory stimuli regulate caspase substrate profiles. Mol. Cell. Proteomics 9(5), 880-893 (2010).
90. Enoksson M, Li J, Ivancic MM et al. Identification of proteolytic cleavage sites by quantitative proteomics. J. Proteome. Res. 6(7), 2850-2858 (2007).
91. Dix MM, Simon GM, Wang C, Okerberg E, Patricelli MP, Cravatt BF. Functional interplay between caspase cleavage and phosphorylation sculpts the apoptotic proteome. Cell 150(2), 426-440 (2012).
92. Piatkov KI, Brower CS, Varshavsky A. The N-end rule pathway counteracts cell death by destroying proapoptotic protein fragments. Proc. Natl Acad. Sci. USA 109(27), E1839-E1847 (2012).
93. Tasaki T, Sriram SM, Park KS, Kwon YT. The N-end rule pathway. Annu. Rev. Biochem. 81 ,261-289 (2012).
94. Prudova A, Auf dem Keller U, Butler GS, Overall CM. Multiplex N-terminome analysis of MMP-2 and MMP-9 substrate degradomes by iTRAQ-TAILS quantitative proteomics. Mol. Cell. Proteomics 9(5), 894-911 (2010).
95. Auf dem Keller U, Prudova A, Gioia M, Butler GS, Overall CM. A statistics-based platform for quantitative N-terminome analysis and identification of protease cleavage products. Mol. Cell. Proteomics 9(5), 912-927 (2010).
96. Starr AE, Bellac CL, Dufour A, Goebeler V, Overall CM. Biochemical characterization and N-terminomics analysis of leukolysin, the membrane-type 6 matrix metalloprotease (MMP25): chemokine and vimentin cleavages enhance cell migration and macrophage phagocytic activities. J. Biol. Chem. 287(16), 13382-13395 (2012).
97. Jefferson T, Auf dem Keller U, Bellac C et al. The substrate degradome of meprin metalloproteases reveals an unexpected proteolytic link between meprin b and ADAM10. Cell. Mol. Life Sci. 70(2), 309-333 (2013).
98. Reiser J, Adair B, Reinheckel T. Specialized roles for cysteine cathepsins in health and disease. J. Clin. Invest. 120(10), 3421-3431 (2010).
99. Laurent-Matha V, Huesgen PF, Masson O et al. Proteolysis of cystatin C by cathepsin D in the breast cancer microenvironment. FASEB J. 26(12), 5172-5181 (2012).
100. Tholen S, Biniossek ML, Gansz M et al. Double deficiency of cathepsins B and L results in massive secretome alterations and suggests a degradative cathepsin-MMP axis. Cell. Mol. Life Sci. doi:10.1007/s00018-013-1406-1 (2013) (Epub ahead of print).
101. Wilson CH, Indarto D, Doucet A et al. Identifying natural substrates for dipeptidyl peptidases 8 and 9 using terminal amine isotopic labeling of substrates (TAILS) reveals in vivo roles in cellular homeostasis and energy metabolism. J. Biol. Chem. 288(20), 13936-13949 (2013).
102. Chowdhury D, Lieberman J. Death by a thousand cuts: granzyme pathways of programmed cell death. Annu. Rev. Immunol. 26 ,389-420 (2008).
103. Bovenschen N, Quadir R, van den Berg AL et al. Granzyme K displays highly restricted substrate specificity that only partially overlaps with granzyme A. J. Biol. Chem. 284(6), 3504-3512 (2009).
104. Van Damme P, Maurer-Stroh S, Hao H et al. The substrate specificity profile of human granzyme A. Biol. Chem. 391(8), 983-997 (2010).
105. Plasman K, Maurer-Stroh S, Ahmad J et al. Conservation of the extended substrate specificity profiles among homologous granzymes across species. Mol. Cell. Proteomics, (2013).
106. Mahrus S, Craik CS. Selective chemical functional probes of granzymes A and B reveal granzyme B is a major effector of natural killer cell-mediated lysis of target cells. Chem. Biol. 12(5), 567-577 (2005).
107. Mahrus S, Kisiel W, Craik CS. Granzyme M is a regulatory protease that inactivates proteinase inhibitor 9, an endogenous inhibitor of granzyme B. J. Biol. Chem. 279(52), 54275-54282 (2004).
108. de Poot SAH, Westgeest M, Hostetter DR et al. Human and mouse granzyme M display divergent and species-specific substrate specificities. Biochem. J. 437(3), 431-442 (2011).
109. Van Damme P, Maurer-Stroh S, Plasman K et al. Analysis of protein processing by N-terminal proteomics reveals novel species-specific substrate determinants of granzyme B orthologs. Mol. Cell. Proteomics 8(2), 258-272 (2009).
110. Plasman K, Van Damme P, Kaiserman D et al. Probing the efficiency of proteolytic events by positional proteomics. Mol. Cell. Proteomics 10(2), M110.003301 (2011).
111. Niessen S, Hoover H, Gale AJ. Proteomic analysis of the coagulation reaction in plasma and whole blood using PROTOMAP. Proteomics 11(12), 2377-2388 (2011).
112. Wildes D, Wells JA. Sampling the N-terminal proteome of human blood. Proc. Natl Acad. Sci. USA 107(10), 4561-4566 (2010).
113. Villanueva J, Shaffer DR, Philip J et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest. 116(1), 271-284 (2006).)
114. Tam EM, Morrison CJ, Wu YI, Stack MS, Overall CM. Membrane protease proteomics: Isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates. Proc. Natl Acad Sci. USA, 101(18), 6917-6922 (2004).
115. Guo L, Eisenman JR, Mahimkar RM et al. A proteomic approach for the identification of cell-surface proteins shed by metalloproteases. Mol. Cell. Proteomics 1(1), 30-36 (2002).
116. Esterházy D, Stützer I, Wang H et al. Bace2 is a b cell-enriched protease that regulates pancreatic b cell function and mass. Cell. Metabolism, 14(3), 365-377 (2011).
117. Kuhn P-H, Koroniak K, Hogl S et al. Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons. EMBO J. 31(14), 3157-3168 (2012).
118. Eichelbaum K, Winter M, Diaz MB, Herzig S, Krijgsveld J. Selective enrichment of newly synthesized proteins for quantitative secretome analysis. Nat. Biotechnol. 30(10), 984-990. (2012).
119. Vögtle FN, Wortelkamp S, Zahedi RP et al. Global analysis of the mitochondrial N-proteome identifies a processing peptidase critical for protein stability. Cell 139(2), 428-439 (2009).
120. Drube J, Schiffer E, Lau E et al. Urinary proteome analysis to exclude severe vesicoureteral reflux. Pediatrics 129(2), e356-e363 (2012).
121. Schiffer E, Bick C, Grizelj B, Pietzker S, Schöfer W. Urinary proteome analysis for prostate cancer diagnosis: cost-effective application in routine clinical practice in Germany. Int. J. Urol. 19(2), 118-125 (2012).
122. Schiffer E, Liabeuf S, Lacroix C et al. Markers of vascular disease in plasma from patients with chronic kidney disease identified by proteomic analysis. J. Hypertens. 29(4), 783-790 (2011).
123. Zhang X, Che F, Berezniuk I, Sonmez K, Toll L, Fricker L. Peptidomics of Cpe mouse brain regions: implications for neuropeptide processing. J. Neurochem. 107(6), 1596-1613 (2008).
124. Che FY, Lim J, Pan H, Biswas R, Fricker LD. Quantitative neuropeptidomics of microwave-irradiated mouse brain and pituitary. Mol. Cell. Proteomics 4(9), 1391-1405 (2005).
125. Che FY, Yuan Q, Kalinina E, Fricker LD. Peptidomics of Cpe fat/fat mouse hypothalamus: effect of food deprivation and exercise on peptide levels. J. Biol. Chem. 280(6), 4451-4461 (2005).
126. Che FY, Fricker LD. Quantitative peptidomics of mouse pituitary: comparison of different stable isotopic tags. J. Mass Spectrom. 40(2), 238-249 (2005).
127. Rawlings ND. A large and accurate collection of peptidase cleavages in the MEROPS database. Database (Oxford), 2009, bap015 (2009).
128. Rawlings ND, Barrett AJ, Bateman A. MEROPS: the peptidase database. Nucleic Acids Res. 38(Database issue), D227-D233 (2010).
129. Lange PF, Overall CM. TopFIND, a knowledgebase linking protein termini with function. Nat. Methods 8(9), 703-704 (2011).
130. Crawford ED, Seaman JE, Agard N et al. The DegraBase: a database of proteolysis in healthy and apoptotic human cells. Mol. Cell Proteomics 12(3), 813-824 (2013).
131. López-Ot?́n C, Hunter T. The regulatory crosstalk between kinases and proteases in cancer. Nat. Rev. Cancer 10(4), 278-292 (2010).
132. Dean RA, Overall CM. Proteomics discovery of metalloproteinase substrates in the cellular context by iTRAQTM labeling reveals a diverse MMP-2 substrate degradome. Mol. Cell Proteomics 6(4), 611-623 (2007).